Table 2.
Drug tested, %Susceptible (n/N Tested) | |||||||
---|---|---|---|---|---|---|---|
AMK | ATM | FEP/CAZ | GEN | MEM/IPM | TZP | TOB | CST |
78.6% (125 of 159) |
7.2% (10 of 139) |
14.4% (21 of 177) |
57.7% (94 of 163) |
3.4% (6 of 179) |
5.8% (10 of 173) |
74.3% (104 of 140) |
91.9% (57 of 62) |
Ceftolozane-tazobactam (n/N tested, % susceptible) | 125 of 139 (89.9%) |
Abbreviations: AMK, amikacin; ATM, aztreonam; CAZ, ceftazidime; CST, colistin; FEP, cefepime; GEN, gentamicin; IPM, imipenem; MEM, meropenem; TOB, tobramycin; TZP, piperacillin-tazobactam.
aMost centers reported results for either FEP or CAZ and MEM or IPM. Results here reflect the combined data for both. Not all centers tested all listed drugs.